General Information of Drug (ID: DMCDYW7)

Drug Name
Nicardipine
Synonyms
Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Indication
Disease Entry ICD 11 Status REF
High blood pressure BA00 Approved [1]
Intracerebral hemorrhage N.A. Approved [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 479.5
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The clearance of drug is 0.4 L/h/kg []
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 8.6 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.17068 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [4]
Vd
The volume of distribution (Vd) of drug is 8.3 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 7.9 mg/mL [3]
Chemical Identifiers
Formula
C26H29N3O6
IUPAC Name
5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
InChI
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
InChIKey
ZBBHBTPTTSWHBA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4474
ChEBI ID
CHEBI:7550
CAS Number
55985-32-5
DrugBank ID
DB00622
TTD ID
D0T0KA
VARIDT ID
DR00280
INTEDE ID
DR1144
ACDINA ID
D00465
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Blocker [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nicardipine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Nicardipine and Nadolol. Essential hypertension [BA00] [11]
Coadministration of a Drug Treating the Disease Different from Nicardipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Major Increased metabolism of Nicardipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Magnesium Sulfate DMVEK07 Moderate Additive hypotensive effects by the combination of Nicardipine and Magnesium Sulfate. Acute pain [MG31] [13]
Emapalumab DMZG5WL Moderate Altered metabolism of Nicardipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [14]
Mitotane DMU1GX0 Major Increased metabolism of Nicardipine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [12]
Siltuximab DMGEATB Moderate Altered metabolism of Nicardipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [14]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Nicardipine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [15]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nicardipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [16]
Zileuton DMVRIC2 Minor Decreased metabolism of Nicardipine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [17]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nicardipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [18]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Nicardipine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Nicardipine and Cariprazine. Bipolar disorder [6A60] [20]
Erdafitinib DMI782S Moderate Increased metabolism of Nicardipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [21]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Nicardipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Decreased metabolism of Nicardipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Mifepristone DMGZQEF Moderate Decreased metabolism of Nicardipine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [24]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Nicardipine and Pasireotide. Cushing syndrome [5A70] [25]
Lumacaftor DMCLWDJ Major Increased metabolism of Nicardipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [12]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nicardipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [26]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nicardipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [27]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Nicardipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [28]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Nicardipine and Selegiline. Depression [6A70-6A7Z] [29]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Nicardipine and Isocarboxazid. Depression [6A70-6A7Z] [29]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Nicardipine and Tranylcypromine. Depression [6A70-6A7Z] [29]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Nicardipine and OPC-34712. Depression [6A70-6A7Z] [20]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Nicardipine and Phenelzine. Depression [6A70-6A7Z] [29]
Primidone DM0WX6I Major Increased metabolism of Nicardipine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Cenobamate DM8KLU9 Moderate Increased metabolism of Nicardipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nicardipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Fosphenytoin DMOX3LB Major Increased metabolism of Nicardipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Ethotoin DMXWOCP Moderate Increased metabolism of Nicardipine caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Phenobarbital DMXZOCG Major Increased metabolism of Nicardipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nicardipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [33]
Miconazole DMPMYE8 Moderate Decreased metabolism of Nicardipine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [16]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Nicardipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [16]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Nicardipine and Metipranolol. Glaucoma [9C61] [34]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Nicardipine and Levobetaxolol. Glaucoma [9C61] [34]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Nicardipine and Levobunolol. Glaucoma [9C61] [34]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Nicardipine and Carvedilol. Heart failure [BD10-BD1Z] [11]
Boceprevir DMBSHMF Moderate Decreased metabolism of Nicardipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Simeprevir DMLUA9D Moderate Decreased metabolism of Nicardipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [36]
Telaprevir DMMRV29 Moderate Decreased metabolism of Nicardipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [35]
Rifampin DMA8J1G Major Increased metabolism of Nicardipine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Rifapentine DMCHV4I Major Increased metabolism of Nicardipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Nicardipine and Procarbazine. Hodgkin lymphoma [2B30] [29]
Delavirdine DM3NF5G Moderate Decreased metabolism of Nicardipine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Nicardipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Cobicistat DM6L4H2 Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [39]
Tipranavir DM8HJX6 Moderate Accelerated clearance of Nicardipine due to the transporter induction by Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [40]
Efavirenz DMC0GSJ Moderate Increased metabolism of Nicardipine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [41]
Saquinavir DMG814N Moderate Decreased metabolism of Nicardipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Etravirine DMGV8QU Moderate Increased metabolism of Nicardipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Nicardipine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Darunavir DMN3GCH Moderate Decreased metabolism of Nicardipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Atazanavir DMSYRBX Moderate Decreased metabolism of Nicardipine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Nicardipine and Acebutolol. Hypertension [BA00-BA04] [11]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Nicardipine and Penbutolol. Hypertension [BA00-BA04] [11]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Nicardipine and Nebivolol. Hypertension [BA00-BA04] [11]
Pindolol DMD2NV7 Moderate Increased risk of cardiac depression by the combination of Nicardipine and Pindolol. Hypertension [BA00-BA04] [11]
Conivaptan DM1V329 Moderate Decreased metabolism of Nicardipine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [46]
Lesinurad DMUR64T Moderate Increased metabolism of Nicardipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [47]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nicardipine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [48]
Amobarbital DM0GQ8N Moderate Increased metabolism of Nicardipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [15]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Nicardipine and Propiomazine. Insomnia [7A00-7A0Z] [20]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Nicardipine and ITI-007. Insomnia [7A00-7A0Z] [20]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nicardipine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [49]
Selpercatinib DMZR15V Moderate Decreased metabolism of Nicardipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
Idelalisib DM602WT Moderate Decreased metabolism of Nicardipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [50]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Nicardipine caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [24]
IPI-145 DMWA24P Moderate Decreased metabolism of Nicardipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [51]
LGX818 DMNQXV8 Moderate Increased metabolism of Nicardipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nicardipine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [14]
Exjade DMHPRWG Moderate Decreased metabolism of Nicardipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [53]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Nicardipine and Thalidomide. Multiple myeloma [2A83] [24]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Nicardipine and Siponimod. Multiple sclerosis [8A40] [24]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Nicardipine and Fingolimod. Multiple sclerosis [8A40] [54]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Nicardipine and Ozanimod. Multiple sclerosis [8A40] [55]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nicardipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [14]
Dasatinib DMJV2EK Moderate Decreased metabolism of Nicardipine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [56]
Modafinil DMYILBE Moderate Increased metabolism of Nicardipine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [24]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Nicardipine and Promethazine. Nausea/vomiting [MD90] [20]
Entrectinib DMMPTLH Moderate Decreased metabolism of Nicardipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [57]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nicardipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [58]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Nicardipine and Safinamide. Parkinsonism [8A00] [29]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Nicardipine and Rasagiline. Parkinsonism [8A00] [29]
Abametapir DM2RX0I Moderate Decreased metabolism of Nicardipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [59]
Lefamulin DME6G97 Moderate Decreased metabolism of Nicardipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [60]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Nicardipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [61]
Enzalutamide DMGL19D Major Increased metabolism of Nicardipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [12]
Silodosin DMJSBT6 Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [62]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Nicardipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [14]
Ixekizumab DMXW92T Moderate Altered metabolism of Nicardipine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [14]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Nicardipine and Levomepromazine. Psychotic disorder [6A20-6A25] [20]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Nicardipine and Fluphenazine. Psychotic disorder [6A20-6A25] [20]
Everolimus DM8X2EH Moderate Decreased metabolism of Nicardipine caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [63]
Tocilizumab DM7J6OR Moderate Altered metabolism of Nicardipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [14]
Canakinumab DM8HLO5 Moderate Altered metabolism of Nicardipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [14]
Rilonacept DMGLUQS Moderate Altered metabolism of Nicardipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [14]
Golimumab DMHZV7X Moderate Altered metabolism of Nicardipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [14]
Sarilumab DMOGNXY Moderate Altered metabolism of Nicardipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [14]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Nicardipine and Quetiapine. Schizophrenia [6A20] [20]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Nicardipine and Mesoridazine. Schizophrenia [6A20] [20]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Nicardipine and Thioridazine. Schizophrenia [6A20] [20]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Nicardipine and Aripiprazole. Schizophrenia [6A20] [20]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Nicardipine and Iloperidone. Schizophrenia [6A20] [20]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Nicardipine and Paliperidone. Schizophrenia [6A20] [20]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Nicardipine and Perphenazine. Schizophrenia [6A20] [20]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Nicardipine and Molindone. Schizophrenia [6A20] [20]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Nicardipine and Thiothixene. Schizophrenia [6A20] [20]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Nicardipine and Trifluoperazine. Schizophrenia [6A20] [20]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Nicardipine and Risperidone. Schizophrenia [6A20] [20]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Nicardipine and Amisulpride. Schizophrenia [6A20] [20]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Nicardipine and Asenapine. Schizophrenia [6A20] [20]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Nicardipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [64]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nicardipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [14]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nicardipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
Armodafinil DMGB035 Moderate Increased metabolism of Nicardipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
LEE011 DMMX75K Moderate Decreased metabolism of Nicardipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [65]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nicardipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [14]
Fostamatinib DM6AUHV Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [66]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [58]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Nicardipine caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [67]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Nicardipine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [20]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Nicardipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [68]
⏷ Show the Full List of 123 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nicardipine 30 mg capsule 30 mg Oral Capsule Oral
Nicardipine 20 mg capsule 20 mg Oral Capsule Oral
Nicardipine 30 mg capsule 30 mg 12 HR Extended Release Capsule Oral
Nicardipine 45 mg capsule 45 mg 12 HR Extended Release Capsule Oral
Nicardipine 60 mg capsule 60 mg 12 HR Extended Release Capsule Oral
Nicardipine 30 mg capsule 30 mg 12 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2559).
2 Nicardipine FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
9 Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
10 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
12 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
13 Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
16 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
17 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
18 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
19 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
20 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
21 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
22 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
23 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
24 Cerner Multum, Inc. "Australian Product Information.".
25 Canadian Pharmacists Association.
26 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
27 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
28 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
29 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
30 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
31 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
32 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
33 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
34 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
35 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
36 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
37 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
38 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
39 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
40 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
41 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
42 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
43 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
44 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
45 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
46 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
47 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
48 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
49 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
51 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
52 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
53 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
56 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
57 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
58 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
59 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
60 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
62 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
63 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
65 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
66 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
67 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
68 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.